Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial

The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B.

Authors

Institutions

Publication Details

Journal
Oncology Research and Treatment
Published
2024-11-15
DOI
https://doi.org/10.1159/000542459
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial

Michael Untch, Volker Hagen, Corinne Vannier, Katja Gratzke et al.
1 citations
Oncology Research and Treatment
Advanced Breast Cancer Therapies
0.42
article

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial

Michael Untch, Volker Hagen, Corinne Vannier, Katja Gratzke, Jens Meiler, Steffen Dörfel, Matthias Zaiß, Norbert Marschner, Anja Welt, Diana Lüftner, Gerlinde Bing, Karin Potthoff, Thomas Kuhn, Cosima V. M. Brucker, Hans Ulrich Siebenbach, Alexander Stein, Lothar Müller, Rüdiger Liersch, Christoph Salat, Manfred Welslau
article en
1 citations

Abstract

The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B.

Oncology Research and TreatmentVol. 48(1-2)
University Medical Center Freiburg (DE), Klinikum Aschaffenburg (DE), Landwirtschaftskammer Niedersachsen (DE), University of Applied Sciences Emden Leer (DE), Paracelsus Medizinische Privatuniversität (DE), Essen University Hospital (DE), Praxis für Humangenetik (DE), Iomedico (Germany) (DE), Praxis für Hämatologie und Onkologie (DE), St.-Johannes-Hospital Dortmund (DE), Onkozentrum Dresden (DE), Immanuel Krankenhaus (DE), Helios Hospital Berlin-Buch (DE)
Good health and well-being
Openalex Percentile: Top 31%
Advanced Breast Cancer Therapies
0.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.